StockData
Pyxis Oncology, Inc. logo

Pyxis Oncology, Inc. (PYXS) stock

PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 5/30
$1.81+0.13 (+7.74%)

Close on Nov 20, 2026Market cap $150.97MP/E –Yield –

Pyxis Oncology free cash flow

Free cash flow is cash from operations minus capital expenditures: the cash available for dividends, buybacks, debt repayment or acquisitions.

Pyxis Oncology's free cash flow for the twelve months ending Dec 31, 2025 was -$63.51M. For fiscal 2025 it was -$63.51M. The highest annual figure on record is -$11.57M in fiscal 2020.

Annual free cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$63.51M–
FY2024Dec 31, 2024-$57.91M–
FY2023Dec 31, 2023-$77.44M–
FY2022Dec 31, 2022-$95.73M–
FY2021Dec 31, 2021-$35.87M–
FY2020Dec 31, 2020-$11.57M–

Quarterly free cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$10.43M–
Q4 FY2024Dec 31, 2024-$19.29M–
Q3 FY2024Sep 30, 2024-$14.67M–
Q2 FY2024Jun 30, 2024-$3.01M–
Q1 FY2024Mar 31, 2024-$20.95M–
Q4 FY2023Dec 31, 2023-$15.25M–
Q3 FY2023Sep 30, 2023-$17.64M–
Q2 FY2023Jun 30, 2023-$13.29M–
Q1 FY2023Mar 31, 2023-$31.25M–
Q4 FY2022Dec 31, 2022-$19.25M–
Q3 FY2022Sep 30, 2022-$24.82M–
Q2 FY2022Jun 30, 2022-$23.84M-1057.1%
Q1 FY2022Mar 31, 2022-$27.83M–
Q4 FY2021Dec 31, 2021-$12.17M–
Q3 FY2021Sep 30, 2021-$7.29M–
Q2 FY2021Jun 30, 2021$2.49M–
Q1 FY2021Mar 31, 2021-$18.90M–
Q4 FY2020Dec 31, 2020-$3.17M–

More Pyxis Oncology figures

See a number that looks wrong?